Literature DB >> 23602910

PGC-1α, mitochondrial dysfunction, and Huntington's disease.

Ashu Johri1, Abhishek Chandra2, M Flint Beal2.   

Abstract

The constant high energy demand of neurons makes them rely heavily on their mitochondria. Dysfunction of mitochondrial energy metabolism leads to reduced ATP production, impaired calcium buffering, and generation of reactive oxygen species. There is strong evidence that mitochondrial dysfunction results in neurodegeneration and may contribute to the pathogenesis of Huntington's disease (HD). Studies over the past few years have implicated an impaired function of peroxisome proliferator-activated receptor (PPAR)-γ coactivator-1α (PGC-1α), a transcriptional master coregulator of mitochondrial biogenesis, metabolism, and antioxidant defenses, in causing mitochondrial dysfunction in HD. Here we have attempted to discuss in a nutshell, the key findings on the role of PGC-1α in mitochondrial dysfunction in HD and its potential as a therapeutic target to cure HD.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  3-NP; 3-nitropropionic acid; 4-hydroxynonenal; 8-OHdG; 8-hydroxy-2′-deoxyguanosine; BAT; Energy metabolism; HD; HNE; Huntington's disease; MBP; MDA; Mitochondrial dynamics; Mitochondrial dysfunction; Mitophagy; NOXNADPH; Neurodegeneration; OXPHOS; Oxidative stress; PGC-1α; PPAR; PPARs; ROS; SIRT1; SIRT3; Therapeutics; brown adipose tissue; malondialdehyde; myelin basic protein; oxidase; oxidative phosphorylation; peroxisome proliferator-activated receptor; peroxisome proliferator-activated receptor-γ coactivator-1α; reactive oxygen species

Mesh:

Substances:

Year:  2013        PMID: 23602910      PMCID: PMC3722269          DOI: 10.1016/j.freeradbiomed.2013.04.016

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  126 in total

1.  Quantitative neuropathological changes in presymptomatic Huntington's disease.

Authors:  E Gómez-Tortosa; M E MacDonald; J C Friend; S A Taylor; L J Weiler; L A Cupples; J Srinidhi; J F Gusella; E D Bird; J P Vonsattel; R H Myers
Journal:  Ann Neurol       Date:  2001-01       Impact factor: 10.422

2.  Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.

Authors:  G D Demetri; C D Fletcher; E Mueller; P Sarraf; R Naujoks; N Campbell; B M Spiegelman; S Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

3.  Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.

Authors:  Patrick Weydt; Victor V Pineda; Anne E Torrence; Randell T Libby; Terrence F Satterfield; Eduardo R Lazarowski; Merle L Gilbert; Gregory J Morton; Theodor K Bammler; Andrew D Strand; Libin Cui; Richard P Beyer; Courtney N Easley; Annette C Smith; Dimitri Krainc; Serge Luquet; Ian R Sweet; Michael W Schwartz; Albert R La Spada
Journal:  Cell Metab       Date:  2006-10-19       Impact factor: 27.287

4.  Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study.

Authors:  Sarah A J Reading; Michael A Yassa; Arnold Bakker; Adam C Dziorny; Lisa M Gourley; Venu Yallapragada; Adam Rosenblatt; Russell L Margolis; Elizabeth H Aylward; Jason Brandt; Susumu Mori; Peter van Zijl; Susan S Bassett; Christopher A Ross
Journal:  Psychiatry Res       Date:  2005-09-30       Impact factor: 3.222

5.  Elevated NADPH oxidase activity contributes to oxidative stress and cell death in Huntington's disease.

Authors:  Antonio Valencia; Ellen Sapp; Jeffrey S Kimm; Hollis McClory; Patrick B Reeves; Jonathan Alexander; Kwadwo A Ansong; Nicholas Masso; Matthew P Frosch; Kimberly B Kegel; Xueyi Li; Marian DiFiglia
Journal:  Hum Mol Genet       Date:  2012-12-07       Impact factor: 6.150

6.  Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons.

Authors:  Emilie Colin; Diana Zala; Géraldine Liot; Hélène Rangone; Maria Borrell-Pagès; Xiao-Jiang Li; Frédéric Saudou; Sandrine Humbert
Journal:  EMBO J       Date:  2008-07-10       Impact factor: 11.598

7.  Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease.

Authors:  Karina Acevedo-Torres; Lexsy Berríos; Nydia Rosario; Vanessa Dufault; Serguei Skatchkov; Misty J Eaton; Carlos A Torres-Ramos; Sylvette Ayala-Torres
Journal:  DNA Repair (Amst)       Date:  2008-11-20

8.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.

Authors:  Alexander V Panov; Claire-Anne Gutekunst; Blair R Leavitt; Michael R Hayden; James R Burke; Warren J Strittmatter; J Timothy Greenamyre
Journal:  Nat Neurosci       Date:  2002-08       Impact factor: 24.884

9.  Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli.

Authors:  Veronica Costa; Marta Giacomello; Roman Hudec; Raffaele Lopreiato; Gennady Ermak; Dmitri Lim; Walter Malorni; Kelvin J A Davies; Ernesto Carafoli; Luca Scorrano
Journal:  EMBO Mol Med       Date:  2010-12       Impact factor: 12.137

10.  Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity.

Authors:  Wenjun Song; Jin Chen; Alejandra Petrilli; Geraldine Liot; Eva Klinglmayr; Yue Zhou; Patrick Poquiz; Jonathan Tjong; Mahmoud A Pouladi; Michael R Hayden; Eliezer Masliah; Mark Ellisman; Isabelle Rouiller; Robert Schwarzenbacher; Blaise Bossy; Guy Perkins; Ella Bossy-Wetzel
Journal:  Nat Med       Date:  2011-02-20       Impact factor: 53.440

View more
  66 in total

1.  Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization.

Authors:  Judith Eschbach; Björn von Einem; Kathrin Müller; Hanna Bayer; Annika Scheffold; Bradley E Morrison; K Lenhard Rudolph; Dietmar R Thal; Anke Witting; Patrick Weydt; Markus Otto; Michael Fauler; Birgit Liss; Pamela J McLean; Albert R La Spada; Albert C Ludolph; Jochen H Weishaupt; Karin M Danzer
Journal:  Ann Neurol       Date:  2014-12-19       Impact factor: 10.422

Review 2.  Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities.

Authors:  Rachel J Harding; Yu-Feng Tong
Journal:  Acta Pharmacol Sin       Date:  2018-04-05       Impact factor: 6.150

3.  Protective effects of exogenous NaHS against sepsis-induced myocardial mitochondrial injury by enhancing the PGC-1α/NRF2 pathway and mitochondrial biosynthesis in mice.

Authors:  Dongshi Liang; Airong Huang; Yimei Jin; Miaomiao Lin; Xiaojiao Xia; Xiaoli Chen; Airong Huang
Journal:  Am J Transl Res       Date:  2018-05-15       Impact factor: 4.060

Review 4.  Metabolic disturbances in diseases with neurological involvement.

Authors:  João M N Duarte; Patrícia F Schuck; Gary L Wenk; Gustavo C Ferreira
Journal:  Aging Dis       Date:  2013-11-30       Impact factor: 6.745

Review 5.  Adaptive cellular stress pathways as therapeutic targets of dietary phytochemicals: focus on the nervous system.

Authors:  Jaewon Lee; Dong-Gyu Jo; Daeui Park; Hae Young Chung; Mark P Mattson
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

6.  mRNA expression levels of PGC-1α in a transgenic and a toxin model of Huntington's disease.

Authors:  Rita Török; Júlia Anna Kónya; Dénes Zádori; Gábor Veres; Levente Szalárdy; László Vécsei; Péter Klivényi
Journal:  Cell Mol Neurobiol       Date:  2014-10-16       Impact factor: 5.046

Review 7.  Links between mitochondrial retrograde response and mitophagy in pathogenic cell signalling.

Authors:  Daniela Strobbe; Soumya Sharma; Michelangelo Campanella
Journal:  Cell Mol Life Sci       Date:  2021-02-23       Impact factor: 9.261

Review 8.  Nrf2--a therapeutic target for the treatment of neurodegenerative diseases.

Authors:  Delinda A Johnson; Jeffrey A Johnson
Journal:  Free Radic Biol Med       Date:  2015-08-14       Impact factor: 7.376

Review 9.  Prospects for neuroprotective therapies in prodromal Huntington's disease.

Authors:  Abhishek Chandra; Ashu Johri; M Flint Beal
Journal:  Mov Disord       Date:  2014-02-26       Impact factor: 10.338

10.  Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity.

Authors:  Xavier Nadal; Carmen Del Río; Salvatore Casano; Belén Palomares; Carlos Ferreiro-Vera; Carmen Navarrete; Carolina Sánchez-Carnerero; Irene Cantarero; Maria Luz Bellido; Stefan Meyer; Gaetano Morello; Giovanni Appendino; Eduardo Muñoz
Journal:  Br J Pharmacol       Date:  2017-11-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.